EARN25

SPPI Stock Sinks on Trial Update

SPPI short sellers are cheering the sell-0ff

Dec 26, 2019 at 10:28 AM
facebook X logo linkedin


Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is one of the biggest losers early on today, down 55.8% at $3.87, after the company's cancer drug poziotinib failed a mid-stage study, with the shares hitting a three-year bottom of $3.61 already as a result. This move could spark bearish analyst attention for the drugmaker, since all five covering brokerage firms came into with "strong buy" recommendations.

Looking at recent options trading, there was a near even split between call buying and put buying. Overall, call buying barely outpaced put buying by a ratio of 1.20 in the past 10 days at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), with peak open interest sitting at the January 2020 5- and 7-strike puts.

Not surprisingly, short interest is also elevated on Spectrum Pharmaceuticals, though it's short-sale restricted today due to the massive move. Based on average daily trading volumes, it'd take roughly eight sessions for SPPI short sellers to cover their bearish bets.

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!